HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

ABSTRACT Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

[1]  P. Easterbrook,et al.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy , 2010, Journal of the International AIDS Society.

[2]  A. Cheng,et al.  K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. , 2007, AIDS.

[3]  B. Gazzard,et al.  The risks and incidence of K65R and L74V mutations and subsequent virologic responses. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  D. Kuritzkes,et al.  High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen , 2012, AIDS.

[5]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[6]  B. Brenner,et al.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. , 2009, HIV therapy.

[7]  A. Antinori,et al.  Early Virological Failure after Tenofovir + Didanosine + Efavirenz Combination in HIV-Positive Patients upon Starting Antiretroviral Therapy , 2005, Antiviral therapy.

[8]  P. Libin,et al.  The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[9]  H. Günthard,et al.  Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  K. Theys,et al.  Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. , 2013, The Journal of antimicrobial chemotherapy.

[11]  Anne-Mieke Vandamme,et al.  Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation , 2007, Current opinion in HIV and AIDS.

[12]  Ravindra K. Gupta,et al.  K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients , 2005, AIDS.